This document discusses multiple sclerosis (MS), a chronic disease that affects the central nervous system. It explores potential environmental and behavioral factors that may increase risks of developing MS, such as vitamin deficiencies, smoking, and substance abuse during adolescence. The document also examines differences in MS rates between regions and countries, with generally higher rates seen in Northern hemisphere countries compared to some Arab countries. It is suggested that developing public health institutions to promote healthy lifestyles from a young age could help reduce MS prevalence over time.

1. Luisetto M.,
Latyshev O.Yu.,
Suchkov S.V.,
Ibrahim G.A.S.,
Akram M.
CURBING STRATEGY OF PROLIFERATION OF SOME FORM OF
MULTIPLE SCLEROSIS
AS ONE OF THE PLANETARY WAYS
OF SOCIAL TRANSFORMATIONS
Abstract: The widespread incidence of multiple sclerosis in the
Northern hemisphere of the Earth (Compston A., Coles A., 2008) is one of
the obstacles to world cultural, scientific and technological development.
Multiple sclerosis contributes significantly to lowering the human
development index and other key indicators of the physical and mental
health of the population. The authors believe that a set of decisive and
quickly implemented measures by a combination of a number of states will
significantly reduce the dependence of mankind on the spread of multiple
sclerosis due by some environmental or behavioral factors and take
the path of intensification of human development.
Key words: multiple sclerosis, human development index, scientific
and technological progress,social transformations.
Of particular concern to the authors is the fact that multiple sclerosis
occurs by the age of 15, less often already in childhood, and in girls - three
times more often than in boys (Brissaud O., Palin K., Chateil JF, Pedespan
JM, 2001). In the future, manifestations of multiple sclerosis are more
common in women than in men (Kurtzke J.F., 1993; Alonso A., Hernán
M.A., 2008). Timely vitaminization, adherence to diet in children, proper
physical preparation and appropriate sanitary and hygienic procedures
must be taken into account in order to create conditions for reducing the
likelihood of multiple sclerosis in children ( modifiable factors ). It will also
make it possible to grow from children full citizens, hardy and purposeful

2. people who are able to progressively develop their talents and even
giftednessin order to put them at the service of society.
The moment of cardinal restructuring of the body in adolescence is
accompanied by a weakening of the control of manifestations on the part of
parents and the medical and pedagogical community. Many teens spend
more time in the company of peers than at home. And a number of
alarming symptoms of the neurological development of multiple sclerosis,
as a rule, falls outside the field of vision of adults who are responsible for
the correct and timely development of the body of their child. The growing
curiosity encourages adolescents to apply addictions observed in adults to
their daily lives and often acquire alcohol, tobacco (Ascherio A., Munger
KL., 2007) and drug addiction, which accelerates and aggravates the
course of the development of the disease with multiple sclerosis. Timely
non-identification by public institutions of adolescents, who in one way or
another weaken their immune system, lack the necessary food, exercise,
etc., will ultimately adversely affectthe fate of this societyitself.
According :
Nazem Ghasemi, et al :
“Multiple sclerosis (MS) is a chronic inflammatory disease
characterized by central nervous system (CNS) lesions that can lead to
severe physical or cognitive disability as well as neurological defects.
Although the etiology and pathogenesis of MS remains unclear, the
present documents illustrate that the cause of MS is multifactorial and
include genetic predisposition together with environmental factors
such as exposure to infectious agents, vitamin deficiencies, and
smoking. These agents are able to trigger a cascade of events in the
immune system which lead to neuronal cell death accompanied by nerve
demyelination and neuronal dysfunction. Conventional therapies for MS are
based on the use of anti-inflammatory and immunomodulatory drugs, but
these treatments are not able to stop the destructionof nerve tissue.” (60)
BrosseauL et al :

3. “The etiology of multiple sclerosis (MS) remains unknown despite
considerable research involving a number of disciplines for many decades.
Cluster analysis was used to disentangle the possible heterogeneity of MS,
based on clinical characteristics of 108 subjects. Further on, a case-control
study was conducted within each subgroup found with the cluster analysis,
to test with more validity environmental risk factors, such as alcohol,
tobacco, medication and drug abuse. The controls with a rheumatoid
arthritis condition were matched to the cases on age, gender and same
postdiagnostic period and were recruited from the same hospital. Three
main groups of MS subjects were obtained from the cluster analysis,
distinguished by the gender, the presence or not of family history and the
degree of severity of their physical disability. The results showed that drug
abuse was the only risk factor with a statistically significant odds ratio for
overall and for the unique female group without familial history of MS.” (56)
Therefore, it is necessary to develop appropriate public institutions
that will help to heal the rising generation and make the possibility of raising
the next healthy generation of citizens the most likely.
A more traditional variant of the development of multiple sclerosis by
the age of 30 (Debouverie M., Pittion-Vouyovitch S., Louis S., Guillemin F.,
2008) prevails in every patient who has passed the period of physical
formation relatively safely. However, this disease, which struck a person in
the prime of life, leaves a significant imprint on the quality of social return
that society expected from this member. The participants in the
microsocium, in which this individual has been successfully realized so far,
are accustomed to pin their hopes on a person who is in a state of mental
and social maturity. Degenerative changes in the myelin sheath of the brain
and spinal cord of their colleagues can cause significant damage not only
to this individual, but also to the totality of social plans and moods. The task
of public institutions is to fully support a person who is in the prime of his
life, to create him maximum opportunities for all-round development. So
that society can be proud of the multiple achievements of its citizen.
Manifesting in the mostdiverse areas of social self-realization.

4. The most common occurrence is the appearance of a primary
progressive form of multiple sclerosis at the age of 50 (Miller D.H., Leary
S.M., 2007). By this age, relative incidence erases gender accents (Miller
D.H., Leary S.M., 2007). For many people, this can become a real tragedy,
because by this age a person already usually manages to gain public
influence, develop a well-deserved authority from his colleagues, relatives
and friends. Someone by the fiftieth anniversary has already published a
collection of essays, someone has been awarded a prestigious prize, and
someone’s invention won the grand prix of the world exhibition. The past
years allow us to hope for a further increase in merit, public recognition, but
multiple sclerosiscan reduce these hopes to zero.
While Russia and a number of European countries are in the zone of
likely high risk of the incidence of multiple sclerosis (Kudryavtseva, 2015),
the United States and most European countries constitute a zone of
uniquely high risk. Long-acting socially depressive mechanisms, an ever-
increasing level of mass stress (Marrie RA., 2004), ignoring environmental
safety requirements from multinational corporations, and other harmful
factors actively contribute to the rejuvenation and ever-expanding spread of
multiple sclerosis. Due to the impact of a combination of negative factors,
the viral and bacterial etiology of multiple sclerosis acquires striking
manifestations (Sriram S. et al., 1999, 2016). As for the countries of the
Arab world, for example, the risk of developing this disease is either low or
probably low (G. Kurtzke, 1964, 1980, 1993), which allows these states to
take quick and serious steps in terms of socio-economic development.
Along with the fundamental development of the economic growth rate,
significant shifts in infrastructure are visible. And the emergence of projects
such as Neom’s hyper-city prompts one to reflect on the fact that the Arab
world is clearly less susceptible to such negative phenomena as multiple
sclerosis and similar mass diseases.
Of course, it is necessary to analyze the situation with multiple
sclerosis at the moment, but already available data (Y. Kuroiva, L. Kurland,
1982; A. Sadovnick, G. Ebers, 1993) indicate that the Japanese, Koreans,
and Chinese are significantly less susceptible to the development of
multiple sclerosis. The high population density in these countries makes it
possible to demonstrate relatively high incidence rates; however, in
traditional terms per 100 thousand people, multiple sclerosis affects at least
two and no more than six people. We understand that in the territory of
these states there is also an abundance of negative factors suggesting the

5. development of multiple sclerosis among their representatives, such as a
high population density, a strong gas contamination of the urban
atmosphere,artificial magnetic fields,etc.
BergamaschiR et al :.
“Some environmental factors have been already associated to increased
risk of multiple sclerosis (MS), but it is plausible that additional factors
might play a role.
To investigate in MS patients the relationship between inflammatory
activity, detected by brain magnetic resonance imaging (MRI) with
gadolinium (Gd), and air pollution, namely, particulate matters with
diameter less than 10 μm (PM10).
We analyzed from 52 remitting MS patients 226 brain MRIs, 34% with
(Gd+MRI) and 66% without (Gd-MRI) T1-Gd-enhancing lesions. Daily
recording of PM10 in the 30 days before MRI examination was obtained by
monitors depending on the residence of subjects.
PM10 levels in the 5, 10, 15, 20, and 25 days before brain MRIs were
higher (plus 16%, 21%, 24%, 25%, and 21%, respectively) with reference
to Gd+MRI versus Gd-MRI. There was a significant association between
Gd+MRI and PM10 levels ( p = 0.013), independent of immune therapies,
smoker status, and season. In patients who had two repeated MRIs with
opposite outcomes (Gd-MRI and Gd+MRI), PM10 levels were strongly
higher in concurrence with Gd+MRI ( p < 0.0001).
Our findings suggest that air pollution may be a risk factor for MS favoring
inflammatory exacerbations.” (61)

6. figure n 1
However, positive factors prevail due to which the preventive task is
realized. Enzyme-containing food products, a positive philosophy adopted
from childhood, historical traditions and religious foundations of these
powers lead to the fact that for the majority of their population, negative
factors affecting the environment on humans cannot prevail over powerful
positive, protective and preventive factors.
The labor collective of the International Mariinsky Academy named
after M.D. Shapovalenko (IMA) aims its efforts both to study and enrich
these countries by adding other positive traditions to other countries and
regions of the planet. So, in the branch of the IMA "Aquaculture" under the
leadership of the doctor of biological sciences Tarik Hattab Al-Maliki (Iraq,
France), studies are being carried out on the adaptation of marine
invertebrates containing a significant amount of vitamins and enzymes in
new climatic conditions. Under the leadership of IMA Vice President Gaber
Ahmed Saad Ibrahim, with the support of IMA President Oleg Yuryevich
Latyshev, experiments are being conducted in the Kingdom of Saudi Arabia
to increase the efficiency of functional nutrition using marine invertebrates
and mollusks, which helps prevent the developmentof multiple sclerosis.
In the branch office of the IMA “Medicine”, two research centers
operate to address the issues of preventing the development of multiple
sclerosis in the population of the countries of the Northern Hemisphere. In
the center of personalized medicine, under the leadership of Doctor of
Medical Sciences Sergey Viktorovich Suchkov, work is underway both to
form an expanded system of means to prevent the development of multiple
sclerosis, and to compensate for its many consequences for the human
body. At the center of basic research in medicine under the guidance of
Doctor of Pharmaceutical Sciences Mauro Luisetto, work is underway to

7. create conditions for proper detoxification of the human body, increase its
immune functions, as well as drug compensation for the effects of the
progressionof multiple sclerosis.
Basis of this work is considering the brain evolutionary approach from
invertebrates to vertebrates , BEE function and evolution , brain immune
systems as well as the brain wasting system.
The same also observing the strange timing in some neurologic disease
like kuru and role played by specific- aspecificimmune system .
LITERATURE
1. Disease Ontology release 2019-05-13 — 2019-05-13 — 2019.
2. Monarch Disease Ontology release 2018-06-29sonu — 2018-06-29 —
2018.
3. Clanet M. Jean-Martin Charcot. 1825 to 1893 (англ.) // The International
MS Journal (англ.)русск.. — 2008. — June (vol. 15, no. 2). — P. 59—
61. — PMID 18782501. Архивировано 30 марта 2019 года.
* Charcot, J. Histologie de la sclerose en plaques (неопр.) // Gazette des
hopitaux, Paris. — 1868. — Т. 41. — С. 554—555. (англ.)
4. Елена Кудрявцева. Болезнь красивых и
талантливых. Коммерсант. kommersant.ru (13 июля 2015). Дата
обращения 15 июля 2015.
5. Debouverie M., Pittion-Vouyovitch S., Louis S., Guillemin F.Natural
history of multiple sclerosis in a population-based
cohort (англ.) // European Journal of Neurology (англ.)русск. : journal. —
2008. — July. — doi:10.1111/j.1468-1331.2008.02241.x. — PMID
18637953. (англ.)
6. Brissaud O., Palin K., Chateil J.F., Pedespan J.M.Multiple sclerosis:
pathogenesis and manifestations in children (фр.) // Arch Pediatr. —
2001. — Сентябрь (т. 8, № 9). — С. 969—978. — PMID
11582940. (англ.)
7. Miller D.H., Leary S.M. Primary-progressive multiple
sclerosis (англ.) // The Lancet. — Elsevier, 2007. — October (vol. 6, no.
10). — P. 903—912. — doi:10.1016/S1474-4422(07)70243-0. — PMID
17884680. (англ.)
8. Kurtzke J.F. Epidemiologic evidence for multiple sclerosis as an
infection (англ.) // Clinical Microbiology Reviews (англ.)русск. : journal. —

8. 1993. — October (vol. 6, no. 4). — P. 382—427. — PMID
8269393. (англ.)
9. Alonso A., Hernán M.A. Temporal trends in the incidence of multiple
sclerosis: a systematic review (англ.) // Neurology (англ.)русск. :
journal. — Wolters Kluwer (англ.)русск., 2008. — July (vol. 71, no. 2). —
P. 129—135. — doi:10.1212/01.wnl.0000316802.35974.34. — PMID
18606967. (англ.)
10. Sriram S. et al. Chlamydia pneumoniae infection of the central
nervous system in multiple sclerosis (англ.) // Annals of neurology. —
1999. — Vol. 46, no. 1. — P. 6—14. Архивировано 7 ноября 2016 года.
11. Dyment D.A., Ebers G.C., Sadovnick A.D. Genetics of multiple
sclerosis (англ.) // The Lancet. — Elsevier, 2004. — February (vol. 3, no.
92). — P. 104—110. — doi:10.1016/S1474-4422(03)00663-X. — PMID
14747002. (англ.)
12. Compston A., Coles A. Multiple sclerosis (англ.) // The Lancet. —
Elsevier, 2002. — April (vol. 359, no. 9313). — P. 1221—1231. —
doi:10.1016/S0140-6736(02)08220-X. — PMID 11955556. (англ.)
13. Ebers G. C., Sadovnick A. D., Dyment D. A., Yee IML, Willer C.
J., Risch N. Parent-of-origin effect in multiple sclerosis: observations in
half-siblings. (англ.) // The Lancet : journal. — Elsevier, 2004. — May 29
(vol. 363). — P. 1773—1774. Архивировано 13 декабря 2010 года. (англ.)
14. Who gets MS?. Multiple Sclerosis Trust (30 декабря 2009). Дата
обращения 18 апреля 2011. Архивировано17 февраля 2012 года. (англ.)
15. Compston A., Coles A. Multiple sclerosis. (англ.) // The Lancet. —
Elsevier, October 2008. — Vol. 372, no. 9648. — P. 1502—1517. —
doi:10.1016/S0140-6736(08)61620-7. — PMID 18970977. (англ.)
16. Marrie RA. Environmental risk factors in multiple sclerosis
aetiology (англ.) // The Lancet : journal. — Elsevier, December 2004. —
Vol. 3, no. 12. — P. 709—718. — doi:10.1016/S1474-4422(04)00933-
0. — PMID 15556803. (англ.)
17. Ascherio A., Munger KL. Environmental risk factors for multiple
sclerosis. Part II: Noninfectious factors. (англ.) // Annals of
Neurology (англ.)русск. : journal. — June 2007. — Vol. 61, no. 6. — P.
504—513. — doi:10.1002/ana.21141. — PMID 17492755. (англ.)
18. Ascherio A., Munger K.L., Simon K.C. Vitamin D and multiple
sclerosis (англ.) // The Lancet. — Elsevier, 2010. — June (vol. 9, no.
6). — P. 599—612. — doi:10.1016/S1474-4422(10)70086-7. — PMID
20494325. (англ.)
19. Hernán M.A., Jick S.S., Olek M.J., Jick H. Recombinant hepatitis
B vaccine and the risk of multiple sclerosis: a prospective
study. (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 2004. — September (vol. 63, no. 5). — P. 838—
842. — PMID 15832457. (англ.)
20. Spitsin S., Koprowski H. Role of uric acid in multiple
sclerosis (неопр.) // Curr. Top. Microbiol. Immunol.. — 2008. — Т.

9. 318. — С. 325—342. — doi:10.1007/978-3-540-73677-6_13. — PMID
18219824. (англ.)
21. M. Munzel. Multiple Sclerosis: The Psychosomatic Consequence
of Unsuccessful Bonding (англ.). — Karger Publishers, 2002. — P. 35—
48. — doi:10.1159/000065898.
22. J. Münch. [Psychosomatic aspects of multiple sclerosis] //
Therapeutische Umschau. Revue Therapeutique. — February 1995. —
Т. 52, вып. 2. — С. 142—145. — ISSN 0040-5930.
23. Blood clotting protein triggers immune attack on
brain (англ.) (9 October 2015). Дата обращения 11 декабря 2015.
24. Cortical neuronal densities and cerebral white matter
demyelination in multiple sclerosis: a retrospective study (англ.).
25. Открыт новый подтип рассеянного склероза. naked-
science.ru. Дата обращения 23 августа 2018.
26. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis:
an expanded disability status scale
(EDSS) (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 1983. — Vol. 33, no. 11. — P. 1444—1452. —
doi:10.1212/WNL.33.11.1444. — PMID 6685237.
27. Коркина М. В., Мартынов Ю. С., Малков Г. Ф. Психические
нарушения при рассеянном склерозе. М., 1986.
28. Davis S.L., Frohman T.C., Crandall C.G., et al. Modeling
Uhthoff's phenomenon in MS patients with internuclear
ophthalmoparesis (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 2008. — March (vol. 70, no. 13 Pt 2). — P. 1098—
1106. — PMID 18287569. (англ.)
29. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A.,
Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin
F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson
A.J., Waubant E., Weinshenker B., Wolinsky JS. Diagnostic criteria for
multiple sclerosis: 2010 revisions to the McDonald
criteria (англ.) // Annals of Neurology (англ.)русск. : journal. — 2011. —
January (vol. 69, no. 2). — P. 292—302. — PMID 21387374. (англ.)
30. Recommended Diagnostic Criteria for Multiple Sclerosis:
Guidelines from the International Panel on the Diagnosis of Multiple
Sclerosis (англ.)
31. The Radiology Assistant : Multiple Sclerosis (англ.).
www.radiologyassistant.nl. Дата обращения 4 апреля 2018.
32. F.D.Lublin. Predicting the Course of Multiple Sclerosis:
Implications for Treatment (англ.) // Medscape Education Neurology &
Neurosurgery : journal. — 2011. — March. (англ.)
33. Disease Modifying Therapies in Multiple Sclerosis. Report of The
Therapeutics and Technology Assessment Subcommittee of the
American Academy of Neurology and The MS Council for Clinical
Practice Guidelines (англ.)

10. 34. Гусев Е.И., Демина Т.Л. Рассеянный склероз // Consilium
Medicum : 2000. — № 2.
35. Scalfari A., Neuhaus A., Degenhardt A., Rice G.P., Muraro P.A.,
Daumer M., and Ebers G.C. The natural history of multiple sclerosis, a
geographically based study 10: relapses and long-term
disability (англ.) // Brain (англ.)русск. : journal. — Oxford University Press,
2010. — Vol. 133, no. 7. — P. 1914—1929. —
doi:10.1093/brain/awq118. — PMID PMC2892939. (англ.)
36. «Разработка стандартов по лечению рассеянного склероза»
(Сайт общероссийской общественной организации инвалидов-
больных рассеянным склерозом)
37. EMA ввело новые ограничения на применение даклизумаба в
терапии рассеянного склероза
38. D.S. Goodin, B.G. Arnason, P.K. Coyle, E.M. Frohman, and D.W.
Paty. The use of mitoxantrone (Novantrone) for the treatment of
multiple sclerosis: Report of the Therapeutics and Technology
Assessment Subcommittee of the American Academy of
Neurology (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 2003. — Vol. 61, no. 10. — P. 1332—1338. (англ.)
39. The PRISMS (Prevention of Relapses and Disability by
Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group; the
University of British Columbia MS/MRI Analysis Group. PRISMS-4:
Long term efficacy on interferon beta-1a in relapsing
MS (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 2001. — June (vol. 56, no. 12). — P. 1628—
1636. — PMID 11425926. Архивировано 1 июля 2010 года. (англ.)
40. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-
remitting multiple sclerosis. II. MRI analysis results of a multicenter,
randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study
Group and the IFNB Multiple Sclerosis Study
Group (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 1993. — No. 43. — P. 662—667. (англ.)
41. Johnson K.P., Brooks BR et al. Copolymer 1 reduces relapse rate
and improves disability in relapsing-remitting multiple sclerosis: results
of a phase III multicenter, double-blind, placebo-controlled trial.
1995 (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 2001. — No. 57. — P. 16—24. (англ.)
42. Johnson K.P., Brooks BR et al. Copolymer 1 reduces relapse rate
and improves disability in relapsing-remitting multiple sclerosis: results
of a phase III multicenter, double-blind placebo-controlled trial. The
Copolymer 1 Multiple Sclerosis Study
Group (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 1995. — No. 45. — P. 1268—1276. (англ.)
43. Clanet M., Radue E.W., Kappos L. et al. A randomized double-
blind , dose-comparison study of weekly interferon beta-1a (Avonex) in
relapsing MS (англ.) // Neurology (англ.)русск. : journal. — Wolters

11. Kluwer (англ.)русск., 2002. — No. 59. — P. 1507—
1517. Архивировано 21 ноября 2008 года. (англ.)
44. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized,
placebo-controlled trial of natalizumab for relapsing multiple
sclerosis (англ.) // The New England Journal of Medicine : journal. —
2006. — Vol. 354, no. 9. — P. 899—910. (англ.)
45. Kingwell E., Koch M., Leung B., Isserow S., Geddes J.,
Rieckmann P., Tremlett H. Cardiotoxicity and other adverse events
associated with mitoxantrone treatment for
MS (англ.) // Neurology (англ.)русск. : journal. — Wolters
Kluwer (англ.)русск., 2010. — June (vol. 74, no. 22). — P. 1822—
1826. — PMID 20427751. (англ.)
46. Berger J.R., Koralnik IJ. Progressive Multifocal
Leukoencephalopathy and Natalizumab — Unforeseen
Consequences (англ.) // The New England Journal of Medicine :
journal. — 2005. — July (vol. 353, no. 4). — P. 414—416. — PMID
15947082. (англ.)
47. Foley J. Recommendations for the Selection, Treatment, and
Management of Patients Utilizing Natalizumab Therapy for Multiple
Sclerosis (англ.) // The American Journal of Managed Care : journal. —
2010. — June (vol. 16, no. 6 Suppl.). — P. 178—183. — PMID
20615054. (англ.)
48. Gironi M., Martinelli-Boneschi F., Sacerdote P., Solaro C.,
Zaffaroni M., Cavarretta R., Moiola L., Bucello S., Radaelli M., Pilato V.,
Rodegher M., Cursi M., Franchi S., Martinelli V., Nemni R., Comi G.,
Martino G. A pilot trial of low-dose naltrexone in primary progressive
multiple sclerosis. (англ.) // Multiple Sclerosis Journal (англ.)русск.. —
2008. — Vol. 14, no. 8. — P. 1076—1083. —
doi:10.1177/1352458508095828. — PMID 18728058. (англ.)
49. Cree B.A., Kornyeyeva E., Goodin DS. Pilot trial of low-dose
naltrexone and quality of life in multiple sclerosis (англ.) // Annals of
Neurology (англ.)русск. : journal. — 2010. — August (vol. 68, no. 2). — P.
145—150. — doi:10.1002/ana.22006. — PMID 20695007. (англ.)
50. The CAMMS223 Trial Investigators. Alemtuzumab vs. Interferon
Beta-1a in Early Multiple Sclerosis (англ.) // The New England Journal of
Medicine : journal. — 2008. — October (vol. 359, no. 17). — P. 1786—
1801. — PMID 18946064. (англ.)
51. National Multiple Sclerosis Society Архивная копия от 13 июня
2011 на Wayback Machine (англ.)
52. Clinical Trials: National MS Society (англ.)
53. Mithu Storoni, Gordon T. Plant. 2015 // The Therapeutic Potential
of the Ketogenic Diet in Treating Progressive Multiple Sclerosis. —
2015-12-29. — 1 с.
54. Alexander Swidsinski, Yvonne Dörffel, Vera Loening-Baucke,
Christoph Gille, Önder Göktas. Reduced Mass and Diversity of the
Colonic Microbiome in Patients with Multiple Sclerosis and Their

12. Improvement with Ketogenic Diet (англ.) // Frontiers in Microbiology. —
2017. — Vol. 8. — ISSN 1664-302X. — doi:10.3389/fmicb.2017.01141.
55. Do Young Kim, Junwei Hao, Ruolan Liu, Gregory Turner, Fu-
Dong Shi. Inflammation-Mediated Memory Dysfunction and Effects of a
Ketogenic Diet in a Murine Model of Multiple Sclerosis (англ.) // PLOS
One (англ.)русск.. — Public Library of Science, 2012-05-02. — Vol. 7, iss.
5. — P. e35476. — ISSN1932-6203. —
doi:10.1371/journal.pone.0035476.
56. Neuroepidemiology. 1993;12(1):6-14.
Drug abuse as a risk factor of multiple sclerosis: case-control analysis
and a study of heterogeneity.
Brosseau L1, Philippe P, Méthot G, Duquette P, Haraoui B.
57) Luisetto M. Brain response in some systemic immune condition-
Toxicological aspects. Insights
Clin Cell Immunol. 2017; 1: 005-008.
58) Luisetto M., et al. “Brain and Immune System: KURU, a Strange
Kind of Disease. An Endogenous Toxicological Process Like?”. EC
Neurology 10.7 (2018).
59) )Luisetto M, Khan FA,
Muhamad A, Mashori GR, Ahmadabadi BN, et
al. Brain washing systems and other circulating
factors in some neurological condition like
Parkinson (Pd) and vascular and diabetic
dementia: How dynamics- saturation of
clearance can act on toxic molecule? J Neurosci
Neurol Disord. 2020; 4: 001-013.
60) Cell J. 2017 Apr-Jun; 19(1): 1–10.
Published online 2016 Dec 21. doi: 10.22074/cellj.2016.4867
PMCID: PMC5241505
PMID: 28367411

13. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-
Based Therapy
Nazem Ghasemi, Ph.D,1 Shahnaz Razavi, Ph.D,1,* and Elham Nikzad,
B.Sc2
Author information Article notes Copyright and License information
Disclaimer
61) Mult Scler. 2018 Oct;24(12):1578-1584. doi:
10.1177/1352458517726866. Epub 2017 Aug 14.
Air pollution is associated to the multiple sclerosis inflammatory activity
as measured by brain MRI.
Bergamaschi R1, Cortese A1, Pichiecchio A2, Berzolari FG3, Borrelli
P3, Mallucci G1, Bollati V4, Romani A1, Nosari G1, Villa S1, Montomoli
C3.